Logo
x

Search category

Subscribe Now

Type 2 Inflammation

Sanofi's Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

Sanofi's Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation

  • May 8, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.